Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Oxford Nanopore appoints Dr John Milton and Clive G. Brown

Abstract:
Oxford Nanopore Technologies Ltd ("Oxford Nanopore") today announces the appointment of Dr John Milton as Director of Nanopore Chemistry and Clive G. Brown as Director of Bioinformatics and IT.

Oxford Nanopore appoints Dr John Milton and Clive G. Brown

Oxford, UK | Posted on June 10th, 2008

Oxford Nanopore is developing nanopore technology into a molecular detection and analysis platform with a broad range of applications including DNA sequencing. Dr Milton and Clive Brown bring outstanding, relevant experience to their roles at the Company.

Dr Milton was previously Senior Director of Research at Solexa, a Cambridge University spin-out. At Solexa he was principal architect of the sequencing-by-synthesis chemistry that formed the basis of the Genome Analyzer, now a leading second generation DNA sequencing technology. His previous experience includes roles at GlaxoWellcome and Xenova.

Clive G. Brown joins Oxford Nanopore from the Wellcome Trust Sanger Institute (WTSI), Cambridge, UK. At the WTSI he played a key role in the adoption, operation and development of 'next generation' DNA sequencing platforms. WTSI has recently submitted hundreds of Gigabases of high quality data to the 1000 genomes project. Prior to this he was Director of Computational Biology & IT at Solexa.

"We are delighted to welcome John Milton and Clive Brown to our team," said Dr Gordon Sanghera, CEO of Oxford Nanopore. "The appointment of two senior executives with an exceptional track record in sequencing technology reflects the acceleration of our programme to deliver a nanopore-based, label-free, single molecule sequencing system. John and Clive bring not only great technical expertise but also a deep understanding of sequencing applications. This knowledge will help us to develop a sequencing system that truly meets the needs of researchers."

####

About Oxford Nanopore Technologies Ltd
Oxford Nanopore is developing nanopore technology, a revolutionary method of molecular detection and analysis with potential for DNA sequencing, diagnostics, drug development and defence applications. The company was founded on the science of Professor Hagan Bayley of the University of Oxford.

The Company's BASE™ technology is a system for DNA sequencing that employs nanopores to process, identify and record DNA bases in sequence. In contrast to current sequencing technologies, nanopores offer a potential method of directly sequencing DNA at single molecule resolution. This removes the need for amplification or labelling, and allows detection from an electrical signal rather than by fluorescence-based CCD imaging. In order to make a breakthrough in speed and cost, other competing technologies require step changes in optics, computation, and CCD camera technologies. Nanopores provide an alternative path to a step-change in the power and cost of DNA sequencing.

Recent interest in the “race for the $1000 genome" illustrates the needs for a sequencing technology that is affordable and powerful enough to enable an exponential increase in research and understanding of the genome. This knowledge will enable a new era in medicine, agriculture, energy, biodiversity, evolutionary biology, genealogy and many other fields.

The nanopore molecular detection system is powerful and versatile beyond its DNA sequencing potential. It can be adapted to detect a wide range of molecules, including other nucleic acids, proteins, small organic molecules and ionic species.

John Milton PhD, Director of Nanopore Chemistry

John followed his PhD in Organic Chemistry with positions at GlaxoWellcome and Xenova, where he specialised in designing new chemical systems that interact with the biological machinery of genetic processing. During his pharmaceutical career he delivered a number of novel therapeutic molecules into the clinic in the areas of HIV, virology, cancer and cancer related multidrug resistance. This included the HIV therapy Lamivudine (Epivir).

In 2001, John joined the Cambridge University spin-out Solexa, where he was principal architect of the novel sequencing-by-synthesis chemistry. As Senior Director of Research, he built and managed a team of 50 scientists, and took the technology through research, scale up, production, manufacturing and productisation for eventual commercial launch of the Genome Analyzer system in late 2006. From seed funding Solexa successfully raised over $150m before eventual sale to Illumina Inc for over $600m in early 2007.

Most recently, John has been closely involved with a number of biotech startups, looking to exploit the vast wealth of new human sequence data in the medical diagnostics field.

Clive G. Brown, Director of Bioinformatics & IT

Clive joined Oxford Nanopore Technologies from the Wellcome Trust Sanger Institute (Cambridge, UK) where he played a key role in the adoption and exploitation of 'next generation' DNA sequencing platforms, culminating in the submission of hundreds of Gigabases of high quality data to the 1000 genomes project.

Prior to this he was Director of Computational Biology & IT at Solexa, where he was integral to the development of the Genome Analyzer (GA). Clive's team built Solexa's high-performance computing infrastructure and supported all of the breakthrough science behind the GA's development. The group also provided the software tools, core algorithms, data and relationship building that enabled subsequent product adoption.

Clive has held various management and consulting positions at GlaxoWellcome, Oxford Glycosciences and other EU- and US-based organisations, where he has worked at the interface between computing and science, ranging from genetics to proteomics. He has also been responsible for several successful commercial data products and holds degrees in Genetics and Computational Biology from the University of York.

For more information, please click here

Contacts:
Dr Gordon Sanghera, CEO
Zoe McDougall, Communications
+44 (0)870 486 1966

Copyright © Oxford Nanopore Technologies Ltd

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Ag/ZnO-Nanorods Schottky diodes based UV-PDs are fabricated and tested May 26th, 2017

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Unveiling the quantum necklace: Researchers simulate quantum necklace-like structures in superfluids May 26th, 2017

Announcements

Ag/ZnO-Nanorods Schottky diodes based UV-PDs are fabricated and tested May 26th, 2017

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Unveiling the quantum necklace: Researchers simulate quantum necklace-like structures in superfluids May 26th, 2017

Tools

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

Nanomechanics, Inc. to Exhibit at the SEM Conference: Nanoindentation experts will attend and exhibit their instruments at the Conference and Exposition on Experimental and Applied Mechanics in Indianapolis May 25th, 2017

Plasmon-powered upconversion nanocrystals for enhanced bioimaging and polarized emission: Plasmonic gold nanorods brighten lanthanide-doped upconversion superdots for improved multiphoton bioimaging contrast and enable polarization-selective nonlinear emissions for novel nanoscal May 19th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Nanobiotechnology

Zap! Graphene is bad news for bacteria: Rice, Ben-Gurion universities show laser-induced graphene kills bacteria, resists biofouling May 22nd, 2017

Sensors detect disease markers in breath May 19th, 2017

Oddball enzyme provides easy path to synthetic biomaterials May 17th, 2017

The brighter side of twisted polymers: Conjugated polymers designed with a twist produce tiny, brightly fluorescent particles with broad applications May 16th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project